Mepolizumab 750 mg vs placebo
Exacerbations · patients with chronic obstructive pulmonary disease
Mepolizumab 750 mg showed no clear difference in number of participants experiencing an exacerbation in 4‐month compared with placebo (low certainty).
1 finding from 1 review
- Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes onlyOdds ratio 9 [0.75, 108.31]1 study · 18 participantsLow